0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Stability of Melphalan Solution for Intravitreal Injection for Retinoblastoma FREE

Emiliano Buitrago, Bsc1; Eduardo Lagomarsino, PhD2; Gabriel Mato, PharmD2; Paula Schaiquevich, PhD1,3
[+] Author Affiliations
1Clinical Pharmacokinetics Unit, Hospital de Pediatría J. P. Garrahan, Buenos Aires, Argentina
2Department of Pharmacy, Hospital de Pediatría J. P. Garrahan, Buenos Aires, Argentina
3National Scientific and Technical Research Council (CONICET), Hospital de Pediatría J. P. Garrahan, Buenos Aires, Argentina
JAMA Ophthalmol. 2014;132(11):1372-1373. doi:10.1001/jamaophthalmol.2014.2324.
Text Size: A A A
Published online

Intravitreal injections for the treatment of retinoblastoma have been gaining relevance among ophthalmologists, supported by reports on outcome and improvement of the administration technique.1 Currently, doses up to 30 μg per injection are used according to an extensively described technique for intravitreal injection that minimizes the risk of extraocular dissemination of tumor cells.2

The commercial form of melphalan (Alkeran) contains 50 mg of melphalan to be reconstituted in 10 mL of vehicle,3 but each intravitreal injection consists of 30 μg of melphalan (its 1667th part). The rest of the vial is discarded. Specifically in countries with limited resources, this procedure may be optimized to prevent disposal of active agent and preserve it for future patients. The package insert states that after dilution (<0.45 mg/mL) of the reconstituted commercial formulation with sterile saline, the administration should be completed within 60 minutes of reconstitution because of the instability of melphalan.3 This degradation corresponds to a spontaneous hydrolysis to monohydroximelphalan and dihydroximelphalan.3,4 A solution of 400 μg/mL of melphalan in saline at 20°C lost 10% of its content in 4.5 hours; the same loss was attained after 2.4 hours at 25°C, a common room temperature in many clinical centers.4

We evaluated the stability of melphalan solution after reconstitution of the commercial product and serial dilution with saline to a final concentration of 300 μg/mL. This concentration was chosen because in our practice we administer 0.1 mL, the volume that contains the most common clinical dose of 30 μg.

METHODS

Reconstitution of melphalan was developed as stated in the package insert.3 After obtaining the 5-mg/mL solution, serial dilutions with saline were made to obtain a 300-μg/mL solution. This final solution was placed in different syringes to determine the stability of melphalan at different times in room conditions (25°C and laboratory light, solution A), stored in a refrigerator (5°C, solution B), and stored in a freezer (−20°C, solution C). Solutions A and B were quantified for melphalan immediately after reconstitution and after 1, 2, 3, 4, 6, and 24 hours. Solution C was analyzed after 6 months of storage by thawing unassisted at room temperature but protected from light. In all cases, 3 aliquots of each syringe were analyzed for melphalan using high-performance liquid chromatography and fluorescence as previously described.5

RESULTS

After 1 hour at room temperature, there was no loss of melphalan. However, the mean loss increased to 68.06% after 24 hours (Table). A 300-μg/mL solution of melphalan was stable at room conditions for 2 hours after reconstitution and dilution, as less than 5% of melphalan content (mean, 4.89%) was lost during this interval.

Table Graphic Jump LocationTable.  Stability of a 300-μg/mL Solution of Melphalan Under Room Conditions and Refrigeration

Similarly, melphalan loss from solutions stored at refrigeration was not significant up to 3 hours (Table). Thereafter, melphalan degraded by more than 10% of that which would be acceptable for patient injection.

Interestingly, melphalan solutions stored at −20°C for 6 months had a mean (SD) difference of 2.57% (1.22%) compared with the fresh solution.

DISCUSSION

Our results show that in clinical practice after melphalan reconstitution and dilution with sterile saline at a concentration of 300 μg/mL for a 30-μg intravitreal dose, the solution should be kept no longer than 2 hours at ambient conditions (25°C) or 3 hours when refrigerated. Additionally, we showed that once a vial of melphalan is reconstituted and diluted to 300 μg/mL, it can be stored at −20°C for 6 months without loss of significant amounts of the drug. However, we emphasize the need to maintain sterile conditions at all times.

ARTICLE INFORMATION

Corresponding Author: Paula Schaiquevich, PhD, Unidad de Farmacocinética Clínica, Hospital de Pediatría J. P. Garrahan, Combate de los Pozos 1881, C1245AAL, Buenos Aires, Argentina (paula.schaiquevich@gmail.com).

Published Online: July 31, 2014. doi:10.1001/jamaophthalmol.2014.2324.

Author Contributions: Dr Schaiquevich had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: All authors.

Acquisition, analysis, or interpretation of data: Buitrago, Lagomarsino, Schaiquevich.

Drafting of the manuscript: Buitrago, Lagomarsino, Schaiquevich.

Critical revision of the manuscript for important intellectual content: Mato, Schaiquevich.

Statistical analysis: Buitrago, Lagomarsino, Schaiquevich.

Obtained funding: Schaiquevich.

Study supervision: Mato, Schaiquevich.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

REFERENCES

Kaneko  A, Suzuki  S.  Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33(12):601-607.
PubMed   |  Link to Article
Munier  FL, Soliman  S, Moulin  AP, Gaillard  MC, Balmer  A, Beck-Popovic  M.  Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track. Br J Ophthalmol. 2012;96(8):1084-1087.
PubMed   |  Link to Article
Alkeran [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007.
Tabibi  SE, Cradock  JC.  Stability of melphalan in infusion fluids. Am J Hosp Pharm. 1984;41(7):1380-1382.
PubMed
Schaiquevich  P, Buitrago  E, Taich  P,  et al.  Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci. 2012;53(7):4205-4212.
PubMed   |  Link to Article

Figures

Tables

Table Graphic Jump LocationTable.  Stability of a 300-μg/mL Solution of Melphalan Under Room Conditions and Refrigeration

References

Kaneko  A, Suzuki  S.  Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33(12):601-607.
PubMed   |  Link to Article
Munier  FL, Soliman  S, Moulin  AP, Gaillard  MC, Balmer  A, Beck-Popovic  M.  Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track. Br J Ophthalmol. 2012;96(8):1084-1087.
PubMed   |  Link to Article
Alkeran [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007.
Tabibi  SE, Cradock  JC.  Stability of melphalan in infusion fluids. Am J Hosp Pharm. 1984;41(7):1380-1382.
PubMed
Schaiquevich  P, Buitrago  E, Taich  P,  et al.  Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci. 2012;53(7):4205-4212.
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

902 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs